{"id":5142,"date":"2024-07-09T05:10:16","date_gmt":"2024-07-09T10:10:16","guid":{"rendered":"https:\/\/ahvmed.com\/?p=5142"},"modified":"2024-07-09T05:10:16","modified_gmt":"2024-07-09T10:10:16","slug":"promising-results-for-vutrisiran-in-cardiac-amyloidosis","status":"publish","type":"post","link":"https:\/\/ahvmed.com\/?p=5142","title":{"rendered":"Promising Results for Vutrisiran in Cardiac Amyloidosis"},"content":{"rendered":"<p>Top line results from a phase 3 trial of vutrisiran (Amvuttra), a new drug from Alnylam for the treatment of transthyretin-mediated amyloidosis with cardiomyopathy, are positive, according to the company. The HELIOS-B study met the primary endpoint, showing a statistically significant reduction, compared with placebo, in the composite of all-cause mortality and recurrent cardiovascular events &#8230;<br \/><a href=\"https:\/\/www.medscape.com\/viewarticle\/positive-top-line-results-vutrisiran-cardiac-amyloidosis-2024a1000cjj\" class=\"button purchase\" rel=\"nofollow noopener\" target=\"_blank\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Top line results from a phase 3 trial of vutrisiran (Amvuttra), a new drug from Alnylam for the treatment of transthyretin-mediated amyloidosis with cardiomyopathy, are positive, according to the company. The HELIOS-B study met the primary endpoint, showing a statistically significant reduction, compared with placebo, in the composite of all-cause mortality and recurrent cardiovascular events<\/p>\n","protected":false},"author":343,"featured_media":5143,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[53],"tags":[],"class_list":{"0":"post-5142","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medicalnewstoday_com"},"menu_order":0,"_links":{"self":[{"href":"https:\/\/ahvmed.com\/index.php?rest_route=\/wp\/v2\/posts\/5142","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ahvmed.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ahvmed.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ahvmed.com\/index.php?rest_route=\/wp\/v2\/users\/343"}],"replies":[{"embeddable":true,"href":"https:\/\/ahvmed.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5142"}],"version-history":[{"count":0,"href":"https:\/\/ahvmed.com\/index.php?rest_route=\/wp\/v2\/posts\/5142\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ahvmed.com\/index.php?rest_route=\/wp\/v2\/media\/5143"}],"wp:attachment":[{"href":"https:\/\/ahvmed.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5142"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ahvmed.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5142"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ahvmed.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5142"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}